CytomX Therapeutics (CTMX) AI Stock Analysis

• Market Cap: $725.18M
• Dividend Yield: N/A
• Average Volume (3M): 3.38M
• Price to Earnings (P/E): 10.2
• Beta (1Y): 2.74
• Revenue Growth: -10.26%
• EPS Growth: 144.62%
• Country: US
• Employees: 119
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.09
• Shares Outstanding: 169,435,400
• 10 Day Avg. Volume: 2,742,221
• 30 Day Avg. Volume: 3,383,991
• PEG Ratio: >-0.01
• Price to Book (P/B): -190.73
• Price to Sales (P/S): 0.63
• P/FCF Ratio: -1.00
• Enterprise Value/Market Cap: 0.54
• Enterprise Value/Revenue: 3.42
• Enterprise Value/Gross Profit: 3.42
• Enterprise Value/Ebitda: 14.87
• 1Y Price Target: $6.50
• Price Target Upside: 51.87% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): >-0.01
• Revenue Forecast (FY): $87.58M

• Rating: 66 Neutral
• Price Target: $4.50 ▲(5.14% Upside)

CytomX Therapeutics' stock score is primarily driven by strong technical momentum and positive earnings call sentiment, highlighting clinical progress and financial stability. However, financial performance concerns, particularly negative equity and cash flow challenges, weigh down the overall score. The stock's valuation is attractive, but the lack of a dividend yield is a minor drawback.

Positive Factors

Clinical Progress

The strong clinical progress of CX-2051 indicates potential for effective cancer treatment, enhancing CytomX's competitive position in oncology.

Financial Stability

A solid cash position ensures operational funding through at least Q2 2027, allowing CytomX to focus on long-term R&D and strategic initiatives.

Strategic Appointment

The new appointment brings strategic planning and business development expertise, likely strengthening CytomX's leadership and execution capabilities.

Negative Factors

Balance Sheet Challenges

Negative equity indicates liabilities exceed assets, posing solvency risks that could limit financial flexibility and stability.

Cash Flow Difficulties

Declining cash flow generation challenges CytomX's ability to fund operations and investments, potentially impacting long-term growth.

Decreased Revenue

A significant revenue drop due to completed obligations may affect short-term financial performance and investor confidence.

CytomX Therapeutics Business Overview & Revenue Model

Company Description

CytomX Therapeutics (CTMX) is a biotechnology company focused on developing innovative cancer therapeutics based on its proprietary Probody platform. This platform enables the creation of targeted therapies that can selectively activate in the tumor microenvironment, thereby minimizing off-target effects and improving the safety and efficacy of cancer treatments. The company operates in the biopharmaceutical sector, primarily developing antibody-drug conjugates (ADCs) and other targeted therapies for various types of cancer.

How the Company Makes Money

CytomX Therapeutics generates revenue through a combination of collaboration agreements, milestone payments, and potential royalties from partnered products. The company collaborates with major pharmaceutical companies to develop its Probody therapeutics, which often includes upfront payments and milestone payments tied to achieving specific development and regulatory milestones. Additionally, upon successful commercialization of partnered products, CytomX may receive royalties on product sales. The strategic partnerships with large pharmaceutical companies enhance its funding capabilities and reduce the financial burden associated with drug development, allowing CytomX to focus on advancing its pipeline of innovative therapies.

CytomX Therapeutics Financial Statement Overview

Summary

CytomX Therapeutics has shown positive revenue growth and improvements in profitability margins, indicating a turnaround in operational performance. However, the company faces significant balance sheet challenges, including negative equity and potential solvency risks. Cash flow difficulties persist, with negative free cash flow trends and challenges in cash conversion. While there are positive signs of operational recovery, financial instability and cash flow concerns present substantial risks to sustainability.

Income Statement

CytomX Therapeutics showed a positive revenue growth rate from 2023 to 2024, with total revenue increasing from $101.21 million to $138.10 million, representing a growth rate of approximately 36.4%. The gross profit margin remained strong at 100% due to no cost of goods sold. However, the net profit margin improved significantly in 2024, reaching approximately 23.1%, compared to a negative margin in 2023. The EBIT and EBITDA margins also turned positive, indicating improved operational efficiency. Despite these improvements, historical volatility and past losses present a risk.

Balance Sheet

The balance sheet reflects a concerning negative equity position in 2024, with stockholders' equity at -$456,000, indicating liabilities exceed assets. The debt-to-equity ratio is not calculable due to negative equity, but total debt decreased over the year. The equity ratio is negative, which poses a significant risk to financial stability. This indicates potential solvency issues despite reducing total debt.

Cash Flow

The cash flow statement shows a deterioration in free cash flow from -$56.88 million in 2023 to -$86.54 million in 2024, indicating a decline in cash generation capabilities. The operating cash flow to net income ratio is negative, suggesting challenges in converting income into cash. Free cash flow to net income is also negative, highlighting cash flow difficulties despite positive net income in 2024. The high variability in cash flows suggests potential liquidity issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	113.63M	138.10M	101.21M	53.16M	37.31M	68.43M
Gross Profit	113.63M	138.10M	101.21M	53.16M	37.31M	68.43M
EBITDA	26.12M	26.76M	-4.31M	-98.89M	-113.34M	-77.97M
Net Income	28.02M	31.87M	-569.00K	-99.32M	-115.87M	-64.82M
Balance Sheet
Total Assets	158.25M	120.53M	201.79M	260.89M	339.41M	358.66M
Cash, Cash Equivalents and Short-Term Investments	143.63M	100.62M	174.51M	193.65M	305.23M	316.12M
Total Debt	5.60M	9.38M	13.97M	18.06M	21.67M	24.87M
Total Liabilities	50.87M	120.99M	249.24M	346.64M	339.87M	366.44M
Stockholders Equity	107.39M	-456.00K	-47.45M	-85.75M	-459.00K	-7.77M
Cash Flow
Free Cash Flow	-72.35M	-86.54M	-56.88M	-112.53M	-120.64M	2.95M
Operating Cash Flow	-72.25M	-86.23M	-56.03M	-110.79M	-119.03M	5.26M
Investing Cash Flow	-30.19M	99.70M	-150.67M	98.26M	22.49M	-18.72M
Financing Cash Flow	96.05M	7.52M	30.23M	648.00K	110.21M	16.89M

CytomX Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.28
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTMX, the sentiment is Positive. The current price of 4.28 is above the 20-day moving average (MA) of 3.95, above the 50-day MA of 3.47, and above the 200-day MA of 2.09, indicating a bullish trend. The MACD of 0.18 indicates Negative momentum. The RSI at 62.93 is Neutral, neither overbought nor oversold. The STOCH value of 93.12 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CTMX.

CytomX Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTMX	66 Neutral	$725.18M	10.23	66.76%	―	-10.26%	144.62%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LXRX	48 Neutral	$519.66M	―	-45.92%	―	1255.21%	74.58%
ARCT	45 Neutral	$242.49M	-4.02	-27.43%	―	-41.53%	-11.32%
KALV	45 Neutral	$731.40M	―	―	―	―	-13.14%
VSTM	44 Neutral	$801.40M	―	-2888.70%	―	33.79%	-26.37%
BCYC	41 Neutral	$518.41M	―	-34.63%	―	-23.43%	-9.84%

CytomX Therapeutics Corporate Events

CytomX Therapeutics Earnings Call Highlights Clinical Progress

CytomX Therapeutics Inc. recently held its earnings call, which conveyed a positive sentiment overall. The company highlighted strong clinical progress and strategic advancements, despite facing challenges such as decreased revenue and adverse events in trials. This optimistic outlook is driven by promising results in key programs and strategic appointments that bolster the company’s future prospects.

CytomX Therapeutics Reports Q3 2025 Financial Results

CytomX Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel, conditionally activated biologics for cancer treatment, utilizing its proprietary PROBODY® therapeutic platform. In its third-quarter 2025 earnings report, CytomX highlighted significant progress in its clinical pipeline, particularly with its lead programs CX-2051 and CX-801. The company is on track to provide a Phase 1 data update for CX-2051 in early 2026, with plans to advance this candidate towards a registrational study for colorectal cancer (CRC). Additionally, CytomX reported promising biomarker data for CX-801, supporting its ongoing combination study with KEYTRUDA® in melanoma.

CytomX Therapeutics Advances CX-2051 Study in Solid Tumors

Study Overview: CytomX Therapeutics Inc. is conducting a first-in-human study titled ‘An Investigational Study of CX-2051 in Participants With Advanced Solid Tumors.’ The study aims to assess the safety, tolerability, and antitumor activity of CX-2051 in adults with advanced solid tumors, marking a significant step in cancer treatment research.